METABOLIC DISORDERS
Denosumab increases bone mineral density in male patients with low BMD
This report has been verified
by one or more authors of the
original publication.
J Clin Endocrinol Metab. 2012 Sep;97(9):3161-9. doi: 10.1210/jc.2012-1569. Epub 2012 Jun 21
242 male patients with low bone mineral density were randomized to receive treatment with denosumab or a placebo to determine the effect of denosumab on bone mineral density in the male population. After 1 year of treatment, the denosumab group demonstrated a significantly greater increase in bone mineral density than the control group at the lumbar spine, total hip, femoral neck, trochanter, and the one third radius. There was also a significant decrease in serum CTX levels in the denosumab group at 15 days. The two groups did not differ significantly with respect to adverse events.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
